Patients will be followed for safety issues, immunologic response and clinical recurrence. Patients will either return to their study site or be contacted by phone for questioning regarding any systemic and local toxicity during the initial 48-72 hours after inoculation. If they return to their study site, the local reaction at the inoculation sites, will be examined and measured. For patients that do not return to the study site, a tool will be given and instructions provided to measure the local reaction. Immunologic response will be monitored primarily by in vivo delayed type hypersensitivity (DTH) reactions but also may be documented by other immunologic assays. All patients will be followed for a total of 36 months to document disease-free status. We plan to enroll 100 patients (50 in each treatment arm randomized 1:1) at a planned accrual rate of 5 patients per month (approximately 0.5-1enrollment per study site per month). With accrual beginning in approximately September 2014, enrollment of the last patient would be expected in approximately September 2016 followed by a three-year follow-up period.